BRAF and metastatic melanoma: Other treatment options for metastatic melanoma include dabrafenib (36), another BRAF inhibitor used specifically in patients with the BRAFV600E mutation, as well as trametinib (25), a MEK1/2 inhibitor used specifically in patients with the BRAFV600E/K mutation.